Pyrotinib dimaleate is the dimaleate salt form of pyrotinib, an orally bioavailable dual kinase inhibitor targeting epidermal growth factor receptor (EGFR/HER-1) and human epidermal growth factor receptor 2 (HER-2). It functions by binding to and inhibiting both EGFR and HER2 receptor tyrosine kinases, thereby suppressing tumor growth and angiogenesis in EGFR/HER2-expressing tumor cells.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Pyrotinib dimaleate?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Pyrotinib
pharmaceutical raw material
Neratinib
pharmaceutical raw material
Neratinib maleate
pharmaceutical raw material
1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl-4,4,4-d3)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-; 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butyn-1-yl-4,4,4-d3)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-p
pharmaceutical raw material
(+/-)-Phenoxybenzamine-d5 HCl (benzyl-2,3,4,5,6-d5)
pharmaceutical raw material
Rac Atomoxetine-d5 Hydrochloride
pharmaceutical raw material
Urapidil-d3 (methoxy-d3)
pharmaceutical raw material
bis((Z)-but-2-enedioic acid);(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide
KLHFGQSCVQPTIN-XUZAKNADSA-N
CCOC1=C(C=C2C(=C(C=NC2=C1)C#N)NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)NC(=O)/C=C/[C@@H]5N(CCC5)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O
Sourcing Pyrotinib dimaleate?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.